X4 Pharmaceuticals announces EMA validation of MAA for mavorixafor
X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare ...
Business Insider13d
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
Committee for Medicinal Products for Human Use (CHMP). The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug ...
WPRI 1221d
Collaborations Pharmaceuticals, Inc. Provides New Insights Into Metabolism of Chemical Warfare Nerve Agents In Humans
CEO of Collaborations Pharmaceuticals, Inc. “The results of this work could contribute to the understanding of which enzymes are involved and how they are removed from the human body or whether ...